About this guide
Some trials really push that boundary, using new science or new designs or new classes of drugs. We've done all that in the last year, becoming the first group in the NCI's National Clinical Trials Network to activate a financial toxicity trial and the first immunotherapy trial for rare cancers.
This spring, we heard about our most innovative treatment trials. Here in Chicago, we'll hear about our most ground-breaking trials arising in our survivorship and prevention and epidemiology committees.
Innovation is not only our group meeting theme for 2017. It's also something we've been living all year long here at SWOG. In January, we submit our next five-year NCTN grant request. It's a recounting of what we've achieved since 2014, and what we plan to achieve through 2024. At this meeting, I'll meet with my leadership team for the last time, in person, to review our grant strategy and writing progress.
Planning for the future is exciting, and I've never felt better about where SWOG is, and where we are headed. Palliative care, immunotherapy, diversity, digital engagement – our new directions are going to lead us to good destinations. For our members – and most importantly, our patients.
As always, thanks for your commitment to SWOG and our clinical trials. Enjoy the meeting here in Chicago.
Charles D. Blanke, MD